First Line Atezolizumab, Paclitaxel, and Bevacizumab (Avastin®) in mTNBC
Status:
Recruiting
Trial end date:
2023-04-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, open-label, single-arm, phase II clinical trial to evaluate to
evaluate the efficacy and safety of first line atezolizumab in combination with paclitaxel
and bevacizumab (Avastin®) in patients with advanced or metastatic triple-negative breast
cancer (mTNBC)